publication date: May. 3, 2019
NCI Trials for May
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
For further information, contact the principal investigator listed.
Phase I – 10204
A Phase Ib Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
University of Texas MD Anderson Cancer Center LAO
Tawbi, Hussein Abdul-Hassan
Phase I – 10249
MLN9708 (Ixazomib) and MLN4924 (Pevonedistat) in Relapsed/Refractory Multiple Myeloma Patients: A Phase 1b Trial
JHU Sidney Kimmel Comprehensive Cancer Center LAO
Phase I – ADVL1712
A Feasibility Trial of MLN4924 (Pevonedistat, TAK 924, IND# 142772) Given in Combination with Azacitidine, Fludarabine, and Cytarabine, in Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia or Relapsed Myelodysplastic Syndrome.
Pediatric Early Phase Clinical Trial Network
Tarlock, Katherine G.
Phase I/II – 10216
A Phase I/II Study of AZD9291(Osimertinib) and CB-839 HCl in Patients with EGFR Mutant Non-Small Cell Lung Cancer
Ohio State University Comprehensive Cancer Center LAO
Owen, Dwight Hall
Phase II – 10272
A Phase II Multi-Institutional Trial to Evaluate Prostate Specific Membrane Antigen (PSMA)-Based PET Imaging of High Risk Prostate Cancer
NCI Center for Cancer Research
Dahut, William L.
Phase II – A031702
Phase II Study of Cabozantinib in Combination with Nivolumab … Continue reading NCI Trials for May 2019
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.